Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

S Koschmieder; S Isfort; LL Teichmann; P Schafhausen; F Heidel; A Hochhaus; M Griesshammer; K Sockel; P Jost; D Wolleschak; K Döhner; JR Goethert; MP Radsak; M Augustin; H Becker; A Giagounidis; M Schaich; M Klausmann; N Von Bubnoff; F Stegelmann; M Kortmann; J Frank; M Hellmich; TH Brümmendorf

doi:10.1182/blood-2023-173225

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

S Koschmieder
, S Isfort
, LL Teichmann
, P Schafhausen
, F Heidel
, A Hochhaus
, M Griesshammer
, K Sockel
, P Jost
, D Wolleschak
, K Döhner
, JR Goethert
, MP Radsak
, M Augustin
, H Becker
, A Giagounidis
, M Schaich
, M Klausmann
, N Von Bubnoff
, F Stegelmann

M Kortmann, J Frank, M Hellmich, TH Brümmendorf

Universitätsklinik für Innere Medizin 5 - Onkologie und Hämatologie

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

2 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	BLOOD
Jahrgang	142
DOIs	https://doi.org/10.1182/blood-2023-173225
Publikationsstatus	Veröffentlicht - 2023
Veranstaltung	65th Annual Meeting of the American-Society-of-Hematology (ASH) - San Diego, USA/Vereinigte Staaten Dauer: 9 Dez. 2023 → 12 Dez. 2023

Zugriff auf Dokument

10.1182/blood-2023-173225

Dieses zitieren

Koschmieder, S., Isfort, S., Teichmann, LL., Schafhausen, P., Heidel, F., Hochhaus, A., Griesshammer, M., Sockel, K., Jost, P., Wolleschak, D., Döhner, K., Goethert, JR., Radsak, MP., Augustin, M., Becker, H., Giagounidis, A., Schaich, M., Klausmann, M., Von Bubnoff, N., ... Brümmendorf, TH. (2023). Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). BLOOD , 142. https://doi.org/10.1182/blood-2023-173225

Koschmieder, S ; Isfort, S ; Teichmann, LL et al. / Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). in: BLOOD 2023 ; Jahrgang 142.

@article{4b0a1308dc724c70b8fbfbb5d6bbcb31,

title = "Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)",

author = "S Koschmieder and S Isfort and LL Teichmann and P Schafhausen and F Heidel and A Hochhaus and M Griesshammer and K Sockel and P Jost and D Wolleschak and K D{\"o}hner and JR Goethert and MP Radsak and M Augustin and H Becker and A Giagounidis and M Schaich and M Klausmann and \{Von Bubnoff\}, N and F Stegelmann and M Kortmann and J Frank and M Hellmich and TH Br{\"u}mmendorf",

year = "2023",

doi = "10.1182/blood-2023-173225",

language = "English",

volume = "142",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "65th Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 09-12-2023 Through 12-12-2023",

}

Koschmieder, S, Isfort, S, Teichmann, LL, Schafhausen, P, Heidel, F, Hochhaus, A, Griesshammer, M, Sockel, K, Jost, P, Wolleschak, D, Döhner, K, Goethert, JR, Radsak, MP, Augustin, M, Becker, H, Giagounidis, A, Schaich, M, Klausmann, M, Von Bubnoff, N, Stegelmann, F, Kortmann, M, Frank, J, Hellmich, M & Brümmendorf, TH 2023, 'Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)', BLOOD , Jg. 142. https://doi.org/10.1182/blood-2023-173225

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). / Koschmieder, S; Isfort, S; Teichmann, LL et al.
in: BLOOD , Jahrgang 142, 2023.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

AU - Koschmieder, S

AU - Isfort, S

AU - Teichmann, LL

AU - Schafhausen, P

AU - Heidel, F

AU - Hochhaus, A

AU - Griesshammer, M

AU - Sockel, K

AU - Jost, P

AU - Wolleschak, D

AU - Döhner, K

AU - Goethert, JR

AU - Radsak, MP

AU - Augustin, M

AU - Becker, H

AU - Giagounidis, A

AU - Schaich, M

AU - Klausmann, M

AU - Von Bubnoff, N

AU - Stegelmann, F

AU - Kortmann, M

AU - Frank, J

AU - Hellmich, M

AU - Brümmendorf, TH

PY - 2023

Y1 - 2023

U2 - 10.1182/blood-2023-173225

DO - 10.1182/blood-2023-173225

M3 - Abstract (Journal)

SN - 0006-4971

VL - 142

JO - BLOOD

JF - BLOOD

T2 - 65th Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 9 December 2023 through 12 December 2023

ER -

Koschmieder S, Isfort S, Teichmann LL, Schafhausen P, Heidel F, Hochhaus A et al. Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). BLOOD . 2023;142. doi: 10.1182/blood-2023-173225